Regulus Therapeutics Inc (NASDAQ:RGLS) shares, rose in value, with the stock price up by 20.16% to the previous day’s close as strong demand from buyers drove the stock to $1.55.
Actively observing the price movement in the recent trading, the stock is buoying the session at $1.29, falling within a range of $1.3405 and $1.6. The value of beta (5-year monthly) is 1.412. Referring to stock’s 52-week performance, its high was $3.00, and the low was $0.83. On the whole, RGLS has fluctuated by 13.97% over the past month.
With the market capitalization of Regulus Therapeutics Inc currently standing at about $102.67 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RGLS’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of RGLS currently trading nearly 13.01% and 20.94% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.38, while the 7-day volatility ratio is showing 6.38% which for the 30-day chart, stands at 8.69%. Furthermore, Regulus Therapeutics Inc (RGLS)’s beta value is 1.21, and its average true range (ATR) is 0.13.
A comparison of Regulus Therapeutics Inc (RGLS) with its peers suggests the former has fared considerably weaker in the market. RGLS showed an intraday change of 20.16% in today’s session so far, and over the past year, it shrunk by -45.04%%.
Data on historical trading for Regulus Therapeutics Inc (NASDAQ:RGLS) indicates that the trading volumes over the past 10 days have averaged 0.2 and over the past 3 months, they’ve averaged 476.23K. According to company’s latest data on outstanding shares, there are 65.50 million shares outstanding.
Nearly 19.71% of Regulus Therapeutics Inc’s shares belong to company insiders and institutional investors own 63.69% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.04 million shares as on 2025-03-14, resulting in a short ratio of 6.49. According to the data, the short interest in Regulus Therapeutics Inc (RGLS) stood at 390.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 2.03 million. The stock has fallen by -1.90% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RGLS stock heading into the next quarter.
